SC
KYMR icon

Stephens Consulting’s Kymera Therapeutics KYMR Stock Holding History

Stephens Consulting’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$411 – 1613
2025
Q1 		$411 Buy
+15
New +$547 ﹤0.01% 1008

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Stephens Consulting's KYMR Position: Q2 2025 in Review

Stephens Consulting sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 15 shares — an estimated $411 sold.

Stephens Consulting first reported a position in KYMR in Q1 2025 and held it in 1 quarter. The position peaked at $411 in Q1 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Stephens Consulting reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 15 Kymera Therapeutics shares in Q2 2025, an estimated $411.
  • Stephens Consulting first reported a position in Kymera Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Kymera Therapeutics position peaked at $411 in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.